What caused the PHASQ stock crash on 28 Jan 2026?

The crash tracks to delisting risk reports, extremely low liquidity and continued losses. MarketBeat flagged potential delisting, and trading fell to **$0.000001** with volume **2,500.00**.

What is Meyka AI’s current rating for PHASQ stock?

Meyka AI rates PHASQ **58.98 (Grade C+)** with a HOLD suggestion. The grade balances cash metrics against losses and sector risk and is not investment advice.

Does Meyka AI forecast upside for PHASQ stock?

Meyka AI's forecast model projects **$0.00** versus current **$0.000001**, implying no modeled upside. Forecasts are projections and not guarantees; positive catalysts would be required for recovery.

Is PHASQ stock tradable and liquid on PNK?

Liquidity is very low: today’s volume **2,500.00** versus avg **22,310.00**. Expect wide spreads and execution risk on PNK in USD trading hours until liquidity improves.

US Stocks

PHASQ PhaseBio (PNK) at $0.000001 on 28 Jan 2026: top losers insight

ByDanny Kontos January 28, 2026

PHASQ stock plunged to $0.000001 on the PNK exchange during market hours on 28 Jan 2026, a collapse of -99.00% that places PhaseBio Pharmaceuticals, Inc. among today’s top losers. Trading volume was 2,500.00 shares, well below the 50-day average of 22,310.00, and the share price now sits near its year low of $0.000001. We examine why the move occurred, how company fundamentals and sector context relate, and what the immediate outlook looks like for investors in the United States and overseas.